Wednesday, February 27, 2019

Financial News Conference Full Year 2018 results

Location: Leverkusen, Baykomm (Bayer‘s Communication Center)


Bayer confirms 2019 Group outlook and 2022 targets

  • Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros
  • EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros
  • Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings
  • Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline
  • Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start
  • Positive safety profile of glyphosate unchanged – Bayer vigorously defending itself against lawsuits
  • Net income at 1.695 billion euros, impacted by one-time effects
  • Core earnings per share at 5.94 euros, above expectations
  • Net financial debt at 35.679 billion euros, significantly better than expected
  • Bayer confirms 2019 Group outlook and 2022 targets




Annual Report 2018


Recording of the Conference

Audio: MP3 for download (50.37 MB, 107:24 min.) (dubbed into English)

Video: Webcast with slides



Follow us:


Twitter Logo     You will find the key statements on Twitter